We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ProPhase Labs (PRPH) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has ProPhase Labs, Inc. (PRPH - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ProPhase Labs, Inc. is one of 1181 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ProPhase Labs, Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for PRPH's full-year earnings has moved 107.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that PRPH has returned about 53.6% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 16.1% on average. This means that ProPhase Labs, Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is RVL Pharmaceuticals PLC (RVLP - Free Report) . The stock is up 27.8% year-to-date.
Over the past three months, RVL Pharmaceuticals PLC's consensus EPS estimate for the current year has increased 16.1%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ProPhase Labs, Inc. is a member of the Medical - Drugs industry, which includes 231 individual companies and currently sits at #104 in the Zacks Industry Rank. Stocks in this group have lost about 25.7% so far this year, so PRPH is performing better this group in terms of year-to-date returns. RVL Pharmaceuticals PLC is also part of the same industry.
ProPhase Labs, Inc. and RVL Pharmaceuticals PLC could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is ProPhase Labs (PRPH) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has ProPhase Labs, Inc. (PRPH - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ProPhase Labs, Inc. is one of 1181 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ProPhase Labs, Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for PRPH's full-year earnings has moved 107.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that PRPH has returned about 53.6% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 16.1% on average. This means that ProPhase Labs, Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is RVL Pharmaceuticals PLC (RVLP - Free Report) . The stock is up 27.8% year-to-date.
Over the past three months, RVL Pharmaceuticals PLC's consensus EPS estimate for the current year has increased 16.1%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ProPhase Labs, Inc. is a member of the Medical - Drugs industry, which includes 231 individual companies and currently sits at #104 in the Zacks Industry Rank. Stocks in this group have lost about 25.7% so far this year, so PRPH is performing better this group in terms of year-to-date returns. RVL Pharmaceuticals PLC is also part of the same industry.
ProPhase Labs, Inc. and RVL Pharmaceuticals PLC could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.